Deadline for Commencement of Exclusivity Payments. In the event that Oxford has not obtained First Regulatory Approval prior to the third Agreement Anniversary Date (i.e. in 2011), Oxford will immediately commence making Exclusivity Payments to StemCell, as described in Subsection 3.1.3, on the third Agreement Anniversary Date, as if it had obtained such First Regulatory Approval.
Appears in 3 contracts
Sources: Supply Agreement (Oxford Immunotec Global PLC), Supply Agreement (Oxford Immunotec Global PLC), Supply Agreement (Oxford Immunotec Global PLC)